MGMT and neoplasm: In the FHSXMU/SPPH cohort, the mortality risk of subtype 2 was 2.553 times higher than that of subtype 1, and there were significant differences between the subtypes in terms of prognosis, pathological grade, tumor volume, MGMT promoter methylation, IDH mutation, and imaging feature expression levels.